Bio-Rad Laboratories, Inc.·Healthcare
Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Healthcare
Medical - Devices
7,700
1980-02-27
1.16

Pre-Market Stock Futures: Futures are trading lower on Tuesday morning after investors returned from the three-day Easter weekend to find a stock market ready to rally after some promising news on the war in Iran and a sense, among some across the financial world, that the market had put in a new bottom. Ed Yardeni,... Here Are Tuesday's Top Wall Street Analyst Research Calls: Ameriprise Financial, Arista Networks, Arm Holdings, Lennar, Morgan Stanley, Rocket Lab, Tractor Supply, Wingstop, Wix.com and More

Allspring Global Investments Holdings LLC cut its holdings in Bio-Rad Laboratories, Inc. (NYSE: BIO) by 4.1% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 129,211 shares of the medical research company's stock after selling 5,556 shares during the period.

HOLMDEL, N.J., March 31, 2026 (GLOBE NEWSWIRE) -- BIO-key ® International, Inc. (Nasdaq: BKYI), a global leader in Identity and Access Management (IAM) and biometric authentication technologies, announced its fourth quarter (Q4'25) and year ended December 31, 2025 (2025) results. BIO-key will host an investor call today at 10:00am ET (details below).

KUALA LUMPUR, MALAYSIA, March 30, 2026 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. ("BGMS," the "Company" or “we,” formerly Cyclacel Pharmaceuticals, Inc.) (NASDAQ: BGMS), a diversified company engaged primarily in the provision of fire safety protection and distribution activities, today announced fourth quarter and full year 2025 financial results and provided a business update.

BKYI: Identity and Biometric Authentication Cybersecurity Provider BIO-key to Host Year-End Investor Call Tues., Mar 31 at 10am ET. Dial-in: 1-877-418-5460

AGOURA HILLS, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), a leader in RNA-based therapeutics, announced today that its subsidiary Sapu Nano will formally introduce its Deciparticle™ nanomedicine platform and present its advancing clinical pipeline at BIO-Europe Spring 2026, where the company has been selected as a Presenting Company.